Amylyx Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Amylyx Pharmaceuticals is Josh Cohen, benoemd in Jan2013, heeft een ambtstermijn van 11.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.42M, bestaande uit 8.4% salaris en 91.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.26% van de aandelen van het bedrijf, ter waarde $ 18.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 3.8 jaar.
Belangrijke informatie
Josh Cohen
Algemeen directeur
US$7.4m
Totale compensatie
Percentage CEO-salaris | 8.4% |
Dienstverband CEO | 11.8yrs |
Eigendom CEO | 4.3% |
Management gemiddelde ambtstermijn | 3.9yrs |
Gemiddelde ambtstermijn bestuur | 3.8yrs |
Recente managementupdates
Recent updates
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$166m |
Mar 31 2024 | n/a | n/a | -US$71m |
Dec 31 2023 | US$7m | US$621k | US$49m |
Sep 30 2023 | n/a | n/a | US$2m |
Jun 30 2023 | n/a | n/a | -US$73m |
Mar 31 2023 | n/a | n/a | -US$149m |
Dec 31 2022 | US$7m | US$539k | -US$198m |
Sep 30 2022 | n/a | n/a | -US$184m |
Jun 30 2022 | n/a | n/a | -US$153m |
Mar 31 2022 | n/a | n/a | -US$121m |
Dec 31 2021 | US$1m | US$418k | -US$88m |
Sep 30 2021 | n/a | n/a | -US$68m |
Dec 31 2020 | US$671k | US$370k | -US$42m |
Compensatie versus markt: De totale vergoeding ($USD 7.42M ) Josh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.36M ).
Compensatie versus inkomsten: De vergoeding van Josh is gestegen terwijl het bedrijf verliesgevend is.
CEO
Josh Cohen (32 yo)
11.8yrs
Tenure
US$7,418,169
Compensatie
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 11.8yrs | US$7.42m | 4.26% $ 18.0m | |
Co-Founder | 11.8yrs | US$7.42m | 4.11% $ 17.4m | |
Chief Financial Officer | 3.8yrs | US$3.51m | 0.14% $ 601.7k | |
Chief Legal Officer & General Counsel | 2.8yrs | US$3.01m | 0.21% $ 888.0k | |
Chief Medical Officer | less than a year | US$2.37m | 0.030% $ 127.8k | |
Chief Technical Operations Officer | no data | geen gegevens | geen gegevens | |
Head of Investor Relations & Communications | no data | geen gegevens | geen gegevens | |
Head of Global Marketing | 3.9yrs | geen gegevens | geen gegevens | |
Chief Human Resources Officer | less than a year | geen gegevens | geen gegevens | |
Head of Canada & GM | 3.6yrs | geen gegevens | geen gegevens | |
Head of Global Market Access | 3.9yrs | geen gegevens | geen gegevens | |
Global Head of Regulatory Affairs | 4.3yrs | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AMLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 10.8yrs | US$7.42m | 4.26% $ 18.0m | |
Co-Founder | 10.8yrs | US$7.42m | 4.11% $ 17.4m | |
Company Secretary & Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Special Advisor & Member of Advisory Board | 3.8yrs | US$51.24k | geen gegevens | |
Independent Chairman of the Board | 9.8yrs | US$385.07k | 1.26% $ 5.3m | |
Chairman of The Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Board Observer & Advisor | 7.3yrs | geen gegevens | geen gegevens | |
Independent Director | 1.7yrs | US$681.15k | 0.081% $ 342.1k | |
Independent Director | 3.4yrs | US$348.59k | 0.0073% $ 31.1k | |
Independent Director | less than a year | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
Independent Director | 3.7yrs | US$342.12k | 0.0058% $ 24.6k |
3.8yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AMLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).